Treatment of older patients with glioblastoma must take into account reduced treatment benefits and increased treatment-related toxicity, as this group of frail patients has a particularly poor prognosis. A new systematic review provides guidance for treating elderly patients, but decision-making in clinical practice faces many challenges.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability
Clinical Epigenetics Open Access 13 December 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zarnett, O. J. et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2014.3739.
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Tsang, D. S. et al. Survival outcomes in elderly patients with glioblastoma. Clin. Oncol. (R. Coll. Radiol.) 27, 176–183 (2015).
Zouaoui, S. et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg. Rev. 37, 415–423 (2014).
Laperriere, N. et al. Optimal management of elderly patients with glioblastoma. Cancer Treat. Rev. 39, 350–357 (2013).
Sijben, A. E. et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J. Neurooncol. 89, 97–103 (2008).
Keime-Guibert, F. et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356, 1527–1535 (2007).
Roa, W. et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22, 1583–1588 (2004).
Malmstrom, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).
Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.J.v.d.B. has received consultancy fees and/or honoraria from Actelion, AMGEN, Cavion, Celldex, Merck Ag, Novocure and Roche, and research support from Abbvie and Roche . J.E.B. declares no competing interest
Rights and permissions
About this article
Cite this article
van den Bent, M., Bromberg, J. The many challenges of treating elderly glioblastoma patients. Nat Rev Neurol 11, 374–375 (2015). https://doi.org/10.1038/nrneurol.2015.82
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.82
This article is cited by
-
Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability
Clinical Epigenetics (2023)
-
Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients—a Tertiary Experience
Indian Journal of Surgical Oncology (2019)
-
Region-Specific Dok2 Overexpression Associates with Poor Prognosis in Human Astrocytoma
Molecular Neurobiology (2018)
-
Brain tumors incidences and a retrospective clinical analysis from a tertiary hospital in India
Journal of Neuro-Oncology (2016)
